Palau
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–<0.01) 1.7 (0.48–3.8)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.011 (<0.01–0.023) 53 (16–112)
Incidence  (includes HIV+TB) <0.01 (<0.01–0.01) 44 (39–50)
Incidence (HIV+TB only)        
Case detection, all forms (%) 87 (77–99)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0 (0–41) 0 (0–0)
MDR-TB cases among notified pulmonary
TB cases
0 (0–3) 0 (0–0)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7   0
Pulmonary, clinically diagnosed 0   0
Extrapulmonary 1   0
       
Total new and relapse 8    
Previously treated, excluding relapses 0    
Total cases notified 8    
Among 8 new and relapse cases:
0 (0%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 7 (100%) 1 7
Laboratory-confirmed RR-/MDR-TB cases     1
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 7 (88)
HIV-positive TB patients 1 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0 (0)
HIV-positive TB patients on antiretroviral therapy (ART) 0 (0)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 100
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 9.6
Culture (per 5 million population) 239.0
Drug susceptibility testing (per 5 million population) 239.0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-31 Data: www.who.int/tb/data